Free tool
FAERS Monitor: Padcev
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761137 or its brand name (Padcev, Enfortumab Vedotin-Ejfv). Reports on generic versions are filed under their own applications.
Reports
7,851
Serious
6,925
88% of reports
Hospitalization
2,685
Death reported
1,561
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- rash1,019
- neuropathy peripheral909
- malignant neoplasm progression893
- diarrhoea503
- pruritus467
- death436
- decreased appetite424
- fatigue423
- off label use362
- alopecia324
- skin disorder314
- pyrexia313
- nausea290
- hyperglycaemia276
- taste disorder265
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 2 |
| 2018 | 1 |
| 2020 | 221 |
| 2021 | 328 |
| 2022 | 877 |
| 2023 | 951 |
| 2024 | 1,165 |
| 2025 | 2,438 |
| 2026 | 1,868 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,308 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| taste disorderSignal | 265 | 35.4 | 31.5 | 8,729 |
| neuropathy peripheralSignal | 909 | 25.8 | 24.3 | 21,569 |
| skin disorderSignal | 314 | 25.5 | 22.8 | 7,295 |
| malignant neoplasm progressionSignal | 893 | 23.6 | 22.1 | 19,192 |
| hyperglycaemiaSignal | 276 | 20.4 | 18.2 | 5,054 |
| rashSignal | 1,019 | 6.3 | 5.9 | 4,598 |
| decreased appetiteSignal | 424 | 4.9 | 4.5 | 1,323 |
| alopeciaSignal | 324 | 4.4 | 4.0 | 862 |
| pruritusSignal | 467 | 3.3 | 3.0 | 741 |
| pyrexiaSignal | 313 | 2.4 | 2.2 | 265 |
| diarrhoeaSignal | 503 | 2.1 | 1.9 | 293 |
| fatigue | 423 | 1.5 | 1.3 | 62 |
| death | 436 | 1.4 | 1.2 | 42 |
| off label use | 362 | 1.1 | 1.0 | 4 |
| nausea | 290 | 1.0 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.